WWFHTX

The prescription drug supply chain, including #PBMs, is now making more money off of those #medicines than the #biopharma companies that developed them. thinkbrg.com/insights/publi… @txhbi From: Berkeley Research Group #BRG

From #PBMs to upcoding – when #HealthInsurance companies inflate patient diagnoses to obtain higher risk-adjusted payments – there’s a clear need for significant reform across the #Medicare system. myrgv.com/opinion/2026/0…

Europe spent years undermining its own pharma sector with misguided price controls – and is now scrambling to recover. The lesson for U.S. policymakers is clear: don't make the same mistakes. Check out our latest blog to learn more: weworkforhealth.org/post/europe-is…

.@RepHoulahan: "China is, if not closing the gap, in some cases has closed the gap and has exceeded our capabilities as well." Read WWFH's blog for more key takeaways from our recent briefing: weworkforhealth.org/post/europe-s-…

“While I appreciate the president’s efforts to lower the costs of prescriptions, this could backfire on Americans. While #MFN may sound good on the surface, the reality is far from it.” @txhbi is.gd/devB9l

“Instead of passing along substantial savings by providing more and deeply discounted care for poor rural and urban patients, many of the largest Minnesota hospitals brazenly used the #340B drug pricing program to accrue greater assets.” @Protectaxpayers is.gd/J8ZLeY

As WWFH Executive Director @DLeonard_DC warned in a recent op-ed, “today’s public investments in basic science are tomorrow’s cures.” With China advancing through sustained state-backed investment, the U.S. cannot afford to lose ground in biopharma innovation. biospace.com/policy/opinion…

Why one independent pharmacy owner compares reimbursements from #PBMs to visiting a casino. #PBMReform @TXPharmAssn citizensvoice.com/2026/03/08/pbm…

New report shows #340B hospitals are more likely to allow aggressive debt collection and legal action against patients. #340BReform @TXDisabilities nclnet.org/new-report-340…

New @ncl_tweets report shows #340B hospitals are more likely to allow aggressive debt collection and legal action against patients. #340BReform @TXDisabilities nclnet.org/new-report-340…

New @USDOL proposal could change how middlemen #PBMs operate. More here on the need for #PBMReform. @NTxCommission realclearhealth.com/articles/2026/…

WY Epilepsy Association founder discusses #patientaccess concerns regarding several healthcare issues including #MFN drug pricing & the need for #PBM and #HealthInsurance reform. @BioNorthTX is.gd/2f7Xpi

Recent @FTC consent order with Express Scripts, one of the Big 3 #PBMs, represents the most consequential structural overhaul of the #PBM industry to date. #PBMReform news.bloomberglaw.com/ip-law/ftc-exp…

Per @CMSGov director, #priorauthorization was weaponized in the 1990s and was the most significant wedge to be jammed between doctors and payers, leading to mistrust of #HealthInsurers. medpagetoday.com/publichealthpo…

.@texmed says it will be watching closely to see whether recent #PBMReform measures translate into fewer administrative hurdles and increased #patientaccess to needed medications. @TXPharmAssn texmed.org/TexasMedicineD…

Learn from @protectaxpayers about a #MedicareAdvantage issue called “upcoding,” when plan sponsors inflate patients’ diagnoses to obtain higher risk-adjusted payments. #InsuranceReformNow riograndeguardian.com/stories/marcha…

How MN hospitals generated more than $1 billion in #340B program revenue in 2024 – more than double what it reported in 2023. More in this @mnhealth report. @txhbi beckershospitalreview.com/pharmacy/minne…

New @NationalGrange report reveals how dual-classification of hospitals affects the #340B program – it redirects rural-designated resources away from rural patients. #340Breform @IAFAccess nationalgrange.org/hospital-dual-…

Per US Rep. Greg Murphy of N.C. – who is also a surgeon – lawmakers have been silent for too long about #HealthInsurance companies' abuses. He says all that is about to change. @stopafib medpagetoday.com/washington-wat…

Learn about the coalition of midsize biotech companies fighting back against @WhiteHouse #MostFavoredNation drug pricing policy. @BioNorthTX fiercebiotech.com/biotech/worrie…

Read how weak oversight and misaligned incentives in #MedicareAdvantage have driven up costs for Texas patients. @protectaxpayers #InsuranceReform #PutPatientsFirst riograndeguardian.com/stories/marcha…